Dexrazoxane Injection, Powder, Lyophilized, For Solution
Product Images NDC 72205-247

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dexrazoxane (NDC 72205-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dexra-inj-250mg-cntr-label (Dexra Inj 250mg Cntr Label)

Dexra-inj-250mg-cntr-label (Dexra Inj 250mg Cntr Label)
Description: This is a pharmaceutical product information for Dexrazoxane, a sterile and pyrogen-free lyophilized injection in single-dose vials. Each vial contains 250 mg of dexrazoxane hydrochloride. It is for intravenous use only and must be reconstituted with Sterile Water for Injection. The reconstituted solution is stable for a limited time and should be stored under refrigeration. Further dilution with Lactated Ringer's Injection is necessary before administration via IV drip. The product is manufactured in India and distributed by Novadoz Pharmaceuticals in the USA. Detailed prescribing information is available and it is recommended to store the product within controlled room temperature.*
FDA Label Image

Dexra-inj-250mg-crtn-label (Dexra Inj 250mg Crtn Label)

Dexra-inj-250mg-crtn-label (Dexra Inj 250mg Crtn Label)
This is information about Dexrazoxane for Injection, a medication used intravenously and stored at controlled room temperature. It is a sterile, pyrogen-free lyophilized product that requires reconstitution with Sterile Water for Injection. After reconstitution, the solution is stable for up to 3 hours when refrigerated. Further dilution with Lactated Ringer's Injection is necessary before administration. The manufacturer is MSN Laboratories in India, and the distributor is Novadoz Pharmaceuticals in Piscataway, New Jersey. The product contains 250 mg of dexrazoxane hydrochloride per vial.*
FDA Label Image

Dexra-inj-500mg-cntr-label (Dexra Inj 500mg Cntr Label)

Dexra-inj-500mg-cntr-label (Dexra Inj 500mg Cntr Label)
This text is a prescription label for a pharmaceutical product containing dexrazoxane hydrochloride. It describes the reconstitution instructions, stability, storage conditions, and administration details of the medication. The drug is for intravenous use only and requires dilution before administration via IV drip. The label also provides contact information for Novadoz Pharmaceuticals LLC and specifies that the product is distributed by Novadoz. It is advisable to consult the accompanying prescribing information for dosage and use instructions.*
FDA Label Image

Dexra-inj-500mg-crtn-label (Dexra Inj 500mg Crtn Label)

Dexra-inj-500mg-crtn-label (Dexra Inj 500mg Crtn Label)
This is a description of Dexrazoxane for Injection, a medication used for intravenous use only. Each vial contains dexrazoxane hydrochloride equivalent to 500 mg dexrazoxane. It is sterile, pyrogen-free Lyophilized and the pH is adjusted with hydrochloric acid. It should be stored at 25°C with allowed excursions from 15° to 30°C. When reconstituted with 50 mL of Sterile Water for Injection, the pH of the solution becomes 1.0 to 3.0. Reconstituted solutions are stable for up to 3 hours if refrigerated. Further dilution with Lactated Ringer's Injection is necessary before administration via IV drip. Discard any unused solutions. Manufacturing details show it is distributed by Novadoz Pharmaceuticals LLC. Detailed dosage and use instructions are provided in the prescribing information.*
FDA Label Image

Dexra-inj-fig-01 (Dexra Inj Fig 01)

Dexra-inj-fig-01 (Dexra Inj Fig 01)
This text provides information about a treatment group involving the administration of FACI/Dexrazoxane. It displays the number of patients in the group based on the cumulative dose of Doxorubicin (mg/m²). The doses range from 350 to 1000+ mg/m².*
FDA Label Image

Dexra-inj-structure (Dexra Inj Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.